Join the Oncology Voice Network. Join for Free
The Loudest Voice in Oncology Might Be Uncredentialed.

The Loudest Voice in Oncology Might Be Uncredentialed.


Share This Article


Summary

Social media has shifted oncology influence. The loudest voices shaping patient decisions may have no clinical credentials at all.

The Loudest Voice in Oncology Might Be Uncredentialed.

One Idea Worth Acting On.

A groundbreaking Phase 3 oncology trial reads out at a major medical congress.

Within minutes, a summary appears online.

It is not posted by the lead investigator.

It is posted by a digital influencer with fifty thousand followers who has misread the safety data.

Before the company's press release hits the wire, the market has already decided what the trial means.

What's Actually Happening

Historically, Medical Affairs and Scientific Communications built their strategies around credentialed KOLs, peer-reviewed journals, and congress podium presentations. The assumption was that expertise controlled the flow of scientific information.

That world no longer exists.

As Dr. Robert Matheis, President and CEO of ISMPP and contributor to Voices of Oncology, explains: digital opinion leaders may be entirely uncredentialed in the areas they discuss, yet they accumulate enormous visibility and credibility online. The internet does not distinguish between expertise and amplification.

A DOL with a large following who posts a simplified — or incorrect — interpretation of your data will often reach more oncologists, patients, and investors than the company's official press release. And they will reach them first.

Why This Matters

Misinformation travels faster than peer-reviewed science. In oncology, where patients are searching desperately for information about their disease and their options, the consequences are direct and serious.

As Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy at Sanofi and contributor to Voices of Oncology, describes: a patient searching for information about their diagnosis can be overwhelmed by conflicting and frightening online content before they ever speak to a physician. The clinical data exists. The accessible, accurate interpretation of that data often does not.

Once a misleading interpretation gains momentum online, correcting the narrative becomes exponentially harder. Physicians encounter the distorted version before seeing the publication. Investors react to viral narratives before understanding the science. The company's carefully constructed clinical story has already been replaced by someone else's version.

Where It Breaks in the Real World

A company spends years building a Scientific Communications Platform designed to establish a unified, credible voice. The platform is launched. The data is strong. The KOL endorsements are in place.

Three days after the first major congress presentation, the most widely shared summary of the trial's results is a tweet from an account the company has never heard of — and the tweet gets the primary endpoint wrong.

The company has no response protocol for social media. The Compliance team is unsure what engagement is permitted. By the time anything official is posted, the incorrect version has been retweeted thousands of times.

What Needs to Change

Digital channels are not optional extensions of the scientific communications strategy. They are now the primary environment where clinical narratives form.

Organizations need DOL monitoring as a standing function — knowing who is commenting on their data, what they are saying, and where their interpretations diverge from the intended message. They need pre-publication response frameworks so that when a mischaracterization appears, the corrective voice is ready.

Compliance concerns about digital engagement are real and manageable. The greater risk is silence — letting a narrative the company did not write define a therapy the company spent a decade developing.

The Bottom Line

If you do not shape your clinical narrative online, someone else will.

And they will do it faster, with fewer facts, to a larger audience.

Add Your Voice — Where are you seeing this? What's working — and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN